10 / 40
Tasa de RG en pacientes
tratados con panitumumab
•
ORR in the panitumumab subgroup according to
RAS
mutation
status at baseline (analyzed using cfDNA from a liquid biopsy):
ORR (not confirmed)
% (95% CI)
Odds ratio (95% CI)
P-value (Fisher’s exact
test)
MAF, cut-off (n)
RAS
wild-type
RAS
mutated
≥ 1% (90 wild-type /
3 mutated)
78.9
(69.0 – 86.8)
33.3
(0.8 – 90.6)
7.5 (0.6 – 86.9)
0.129
≥ 0.1% (88 wild-type
/ 5 mutated)
78.4
(68.4 – 86.5)
60.0
(14.7 - 94.7)
2.4 (0.4 – 15.6)
0.315
≥ 0.02% (80 wild-
type / 13 mutated)
80.0
(69.6 – 88.1)
61.5
(31.6 – 86.2)
2.5 (0.7 – 8.7)
0.160
García-Alfonso et al. ESMO congress 2018; Abstract 3887 (and poster discussion)
Preliminary Results
FUTURO:
INVESTIGAR EL PUNTO DE CORTE ÓPTIMO DE MAF
PAPEL DE LA BIOPSIA LIQUIDA EN LA PREDICCIÓN PRECOZ DE RESPUESTA Y DE
RESISTENCIA AL TRATAMIENTO